



The ATOM Coalition

Access! 2023 & IGBA Partnership Luncheon
February 15, 2023



Access to cancer medicines in LMICs



10 million+ people died of cancer in 2020 – 70% of these deaths occurred in LMICs.



WHO forecasts that the majority of cancer deaths will occur in LMICs in the next 10 years.



A recent study showed only 50% of WHO EML medicines are available in LMICs.



Access to medicines is a key priority for WHO (in the context of NCDs).



Sustainable, long-term solutions are difficult to establish.





A recent study showed only 50% of WHO EML medicines are available in LMICs.

Who we are

The **Access to Oncology Medicines (ATOM) Coalition** is an innovative partnership of nearly 40 partners taking collective action to improve access and capacity to use essential life-saving cancer medicines and diagnostics in low- and lower-middle income countries.

Three pillars of work



1. Improving the capacity to receive and use cancer medicines in targeted LLMICs.



2. Making available more WHO EML generic and biosimilar cancer medicines over time.



3. Securing an increasing number of patented medicines and new medicines in the pipeline from biopharma over time.

Our approach

- Developing country solutions in a sustainable and scalable way.
- Complementing existing models and amplifying them through an innovative, multi-sectoral access mechanism.
- Bringing together partners from across sectors at the global, regional and national level with expertise and track records in addressing key access barriers.

Our ambition is to reduce avoidable suffering and deaths caused by cancer in low and lower middle-income countries through increased access to affordable essential cancer medicines and training on their use.

Our partners (and growing)





Country engagement

46

Targeting 46 LLMICs in the next decade, reaching a population of 2.6bn.

10

Delivering capacity development in 10 target coalition countries across five regions.

Target list of essential cancer medicines for ATOM Coalition countries



Generic/Biosimilar medicines




Streamlined list of patented medicines via MPP facilitated VLs



Pathology and diagnostic capacity support

"Simply making medicines available does not guarantee that people living with cancer will receive the medicines they need at the right time."

-Prof. Anil D'Cruz, President, UICC



ATOM Coalition
Partner Novartis is the
first pharma company
to announce a VL for a
cancer medicine,
Nilotinib

Priority Essential Medicines

Priority medicines include generics, biosimilars and patented meds currently on the WHO EML, with ambition to include new medicines in the pipeline in time

Focus on cancers with the highest burden in LLMICs: Breast, Lung, Colorectal, Prostate, Cervical and Childhood cancers

Ambition: increase access to generics:

- focus first on breast cancer medicines and adjuvant therapies.
- expand to other medicines following EML guidelines for other high-incidence cancers (prostate, cervical, lung, colorectal, paediatric).

Companies will engage their medicines portfolio by:

- extending their donation programmes to other ATOM Coalition countries
- exploring pricing options for ATOM Coalition countries and/or
- considering a VL pathway through MPP



What we are asking for

1.

Initial donation programs that can be converted into a sustainable access program over time



2.

Increased number of essential oncology medicines PQ'd and added to the WHO CRP process



3.

Reduced pricing for ATOM Coalition target countries of essential oncology medicines in their portfolio



4.

Additional seed funding



What we offer

1.

Creation of a larger market to hopefully achieve lower prices for medicines and equipment in countries able to use the medicines



2.

Coordination of capacity building activities and efforts across multiple target LLMICs, pooling resources and know-how together in an unprecedented way



3.

Potential support/guidance in overcoming country-level registration barriers





atom@uicc.org



uicc.org/ATOMCoalition



ATOM
Access to Oncology Medicines



Capacity Building countries

Côte d'Ivoire
El Salvador
Honduras
India
Mongolia
Nepal
Pakistan
Senegal
Uganda
Zambia



Targeting all regions, except Europe.

